SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
ASX Faces Legal Action Over Failed Blockchain CHESS Project 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
SpaceX Shares Surge as Wall Street Backs AI Growth Potential 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
CBA Posts Record A$10.98B Profit Despite Cautious Outlook 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Add as a preferred source on Google
Philips, the Dutch manufacturer of medical devices, announced on Monday its decision to pay $1.1 billion in a settlement related to its global ventilator recall, which affects devices used for treating sleep apnea in the United States.
The company emphasized that this settlement does not include an admission of fault or liability but mentioned that it concludes the ongoing uncertainty regarding U.S. litigation.
Financial Impact and Market Response
US News noted that Philips has been under intense scrutiny for the past three years due to the recall of millions of its breathing devices and ventilators.
The recall was due to the potential degradation and toxicity of foam used in these devices, posing severe health risks, including cancer. This issue significantly affected Philips' market valuation, erasing about two-thirds of its value as investors braced for substantial litigation expenses.
Consent Decree and Operational Changes
Earlier in the month, Philips detailed a consent decree with U.S. authorities finalized in January, outlining necessary enhancements at its Respironics plants in the U.S. CEO Roy Jakobs remarked, "The approved consent decree and now the resolution of the personal injury and medical monitoring litigation in the U.S. are significant milestones..."
Financial Arrangements and Insurance Compensation
Additionally, Philips announced an agreement with its insurers for a compensation of 540 million euros ($580 million) related to product liability costs. The settlement, which will boost the company's second-quarter earnings in 2024, has been accommodated in the first-quarter financial results of 2023, with a provision of 982 million euros earmarked for settlement payments, expected to be financed through the following year's cash flow.
First-Quarter Earnings Surpass Expectations
According to Reuters, despite the legal and financial hurdles, Philips reported an 8% increase in core profit during the first quarter, totaling 388 million euros, surpassing the analyst predictions of 361 million euros. The company experienced a 2.4% growth in comparable sales, leading to a profit margin higher than anticipated at 9.4%.
However, order intake declined by 3.8%, primarily due to slow sales in China. CEO Jakobs commented on the positive outlook outside China and emphasized substantial margin improvements as part of their annual plan.
Photo: Philips Newsroom
